Guardant Health said it is gathering real-world validation data for its multi-cancer detection (MCD) assay, Shield MCD, which currently operates as an opt-in component to its FDA-approved colorectal screening test. The company is collecting data to refine assay performance in an intended-use setting and to prepare for a potential regulatory submission. The blood-based test relies on DNA methylation and targets nine additional cancers beyond colorectal, and Guardant reported prior retrospective performance metrics including high specificity and moderate sensitivity across detected cancer types. In parallel, the Guardant platform strategy underscores the ongoing shift from purely trial-based performance claims toward real-world calibration and evidence generation as developers seek broader adoption.